Gilead stock at 52-week high after FDA Yescarta label change, with earnings next
Gilead shares rose 2.1% to a 52-week high of $152.50 after the FDA cleared a label update for Kite’s Yescarta therapy in rare brain lymphoma. CEO Daniel O’Day exercised and sold 115,640 shares under a pre-set plan. The FDA decision removes a prior use limitation for Yescarta in relapsed or refractory primary CNS lymphoma.